Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 5/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.36 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.36 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10590087 | 1.00 | SLC5A2 (0.45) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL13590060 | 1.00 | SLC5A2 (0.45) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL4398458 | 0.90 | SLC5A2 (0.40) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL4398460 | 0.90 | SLC5A2 (0.40) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL4633309 | 0.90 | SLC5A2 (0.53) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL7155412 | 0.90 | SLC5A2 (0.53) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL31135220 | 0.90 | SLC5A2 (0.41) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL7154382 | 0.90 | SLC5A2 (0.41) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL14261165 | 0.82 | ALDH1A1 (0.35) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL14270049 | 0.82 | ALDH1A1 (0.35) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110643222-A | Printing ink | TCL集团股份有限公司 | 2020-01-03 | — | — | CN | claimed |
| JP-62283952-A | — | — | None | — | — | JP | disclosed |
| JP-62283943-A | — | — | None | — | — | JP | disclosed |
| CN-110643222-A | Printing ink | TCL集团股份有限公司 | 2020-01-03 | — | — | CN | disclosed |
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| EP-2177526-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
| US-7629400-B2 | Image making medium | HYMAN SYDNEY | 2009-12-08 | — | — | US | disclosed |
| JP-2006225345-A | SIMPLE SYNTHETIC METHOD FOR OPTICALLY ACTIVE 1-PYRROLINE-N-OXIDE | YOSHIMURA TOSHITSUGU | 2006-08-31 | — | — | JP | disclosed |
| US-20040073045-A1 | Pyrrolidine derivative and process for producing the same | EISAI CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| US-20030035917-A1 | Image making medium | HYMAN SYDNEY (US) | 2003-02-20 | — | — | US | disclosed |
| US-5198322-A | Positively operating radiation-sensitive mixture containing a polyfunctional α-diazo-β-keto ester and radiation-sensitive recording material containing this mixture | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-03-30 | — | — | US | disclosed |
| US-4996301-A | Polyfunctional α-diazo-β-keto esters and their use in light-sensitive compositions | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-02-26 | — | — | US | disclosed |
| EP-0098456-B1 | PEPTIDES COMPRISING A (1S,2R,3R)- OR (1R,2S,3S)-1-NITRILO-1-CARBONYL-3-METHYL-2-OXY-HEPTANE OR -HEPT-5-ENE RESIDUE USEFUL IN THE TOTAL SYNTHESIS OF CYCLOSPORINS, AND PROCESSES FOR THEIR PRODUCTION | SANDOZ AG (CH) | 1989-05-24 | — | — | EP | disclosed |
| JP-S62283952-A | THREITOL DERIVATIVE AND PRODUCTION THEREOF | TAISHO PHARMACEUT CO LTD | 1987-12-09 | — | — | JP | disclosed |
| JP-S62283943-A | THREITOL COMPOUND AND PRODUCTION THEREOF | TAISHO PHARMACEUT CO LTD | 1987-12-09 | — | — | JP | disclosed |
| EP-0098457-B1 | (1S,2R,3R)- AND (1R,2S,3S)-NITRILO-1-CARBONYL-3-METHYL-2-OXY-HEPTANES AND -HEPT-5-ENES USEFUL IN THE TOTAL SYNTHESIS OF CYCLOSPORINS AND PROCESSES FOR THEIR PRODUCTION | SANDOZ AG (CH) | 1987-08-05 | — | — | EP | disclosed |
| US-4554351-A | STEREOISOMERS | SANDOZ LTD. (CH) | 1985-11-19 | — | — | US | disclosed |
| EP-0034567-B1 | A METHOD FOR THE TOTAL SYNTHESIS OF CYCLOSPORINS AND NOVEL CYCLOSPORINS | SANDOZ AG (CH) | 1984-11-07 | — | — | EP | disclosed |
| US-4396542-A | Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production | SANDOZ LTD. (CH) | 1983-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | DCLRE1A, AZI2, CHD9 | SLC5A2 4811/4885CYP2C19 60/4885CYP3A4 1260/4885 |
| US-20040073045-A1 | Pyrrolidine derivative and process for producing the same | DHPS, SQLE, FDFT1 | SLC5A2 3544/4885CYP2C19 1775/4885CYP3A4 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.